Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457203 | 0.80 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL160448 | 0.76 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL1647291 | 0.75 | CES2 (0.39) | TRPA1CYP3A4 | |
| SCHEMBL31448284 | 0.75 | CES2 (0.39) | TRPA1CYP3A4 | |
| SCHEMBL17650908 | 0.72 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL17650996 | 0.72 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL1020714 | 0.68 | MAPT (0.32) | GABRA1GABRB2 | |
| SCHEMBL22602515 | 0.68 | ALDH1A1 (0.30) | — | |
| SCHEMBL14683171 | 0.68 | — | — | |
| SCHEMBL1952585 | 0.68 | MAPK1 (0.38) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076519-B1 | NOVEL DITHIOLOPYRROLONES AND THEIR THERAPEUTICAL APPLICATIONS | CELESTIAL PHARMACEUTICALS SHENZHEN LTD (CN) | 2014-01-15 | — | — | EP | disclosed |
| US-8071637-B2 | Dithiolopyrrolones compounds and their therapeutic applications | WELICHEM BIOTECH INC. (CA) | 2011-12-06 | — | — | US | disclosed |
| US-20100041729-A1 | DITHIOLOPYRROLONES COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | CELESTIAL PHARMACEUTICALS (SHENZHEN) LTD. (CN) | 2010-02-18 | — | — | US | disclosed |
| EP-2076519-A2 | NOVEL DITHIOLOPYRROLONES AND THEIR THERAPEUTICAL APPLICATIONS | Celestial Pharmaceuticals (Shenzhen) LTD. (CN) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008038175-A2 | DITHIOLOPYRROLONES COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | CELESTIAL PHARMACEUTICALS (SHENZHEN) LTD. (CN) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041729-A1 | DITHIOLOPYRROLONES COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | CD4, NDUFS3, TXN2 | GABRA1 4341/4885GABRB2 4650/4885TRPA1 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.